Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In a controlled trial conducted over a six-month period in Mali, subcutaneous administration of the monoclonal antibody L9LS to children aged 6 to 10 achieved an efficacy rate of up to 77% in preventing clinical malaria.
Allergy & Immunology May 6th 2024